What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Participants will receive 6 weekly instillations of TARA-002. Participants confirmed to have a CR at Week 12 will enter the maintenance treatment period and will receive 3 additional weekly instillations of TARA-002 every 3 months up to Month 19, and then 3 weekly doses at Month 25. Participants who are eligible for reinduction at Week 12 will receive 6 additional weekly instillations of…”In the company’s words, NCT07480356 on ClinicalTrials.gov
- Tested for
- Bladder (Urothelial, Transitional Cell) Cancer, Non-Muscle Invasive Bladder Carcinoma, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ, Lymphatic Malformation, Non-muscle Invasive Bladder Cancer
- Main trialPhase 3
- “The goal of this clinical trial is to learn if TARA-002 can treat high-grade non-muscle invasive bladder cancer (NMIBC) in BCG-naïve adults 18 years of age or older. The main questions it aims to answer are: * Can the study drug help participants with this type of cancer? * Is the study drug safe? * What are the side effects of the study drug? Researchers will compare TARA-002 to chemotherapy to see if TARA-002 works to treat NMIBC.”In the company’s words, NCT07480356 on ClinicalTrials.gov
Other drugs for Bladder (Urothelial, Transitional Cell) Cancer
- Cretostimogene GrenadenorepvecCG Oncology, Inc. · Phase 3
- Nogapendekin alfa inbakiceptImmunityBio · Phase 2/3
- NDV-01Relmada Therapeutics, Inc. · Phase 3
- TAR-210Johnson & Johnson (Janssen) · Phase 3
- Alpha1HHamlet Pharma AB · Phase 3
- SasanlimabPfizer · Phase 3
Coming up3
- DecPhase 2 trial completes · ClinicalTrials.gov
- Apr 2028Phase 3 trial completes · ClinicalTrials.gov
- Oct 2031Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials5
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Apr 2028 | Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer | |
| Phase 2Recruiting | Dec 2026 | Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of Age | |
| Phase 2Recruiting | Oct 2031 | Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer | |
| Phase 1Completed | 3 Sep 2024 | Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1a) | |
| Phase 1Completed | 12 Sep 2024 | Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1b) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026